Hinge Health Inc (HNGE)

$HNGE Share Price: $43.19 Contract Selected: Dec 18, 2026 $60 Calls Buy Zone: $2.89 – $3.57 Target Zone: $4.96 – $6.06 Potential Upside: 62% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/

$HNGE RSI: 44.38, MACD: -1.2735 Vol: 2.76, MA20: 39.59, MA50: 40.09 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$NTRA $GH $HNGE $GRAL Isnt i told you?

$NTRA $GH $HNGE $GRAL They will trade higher from here imo. A massive shift rotation is coming to healthcare stocks with these 6 months pullback. Time to accumulate. Mark my words!!! Not today for sure. Give these stocks 4 weeks time frame they are higher from here.

$GH $HNGE $NTRA Including GRAL at 45

$NTRA $GH $HNGE These healthcare stocks which pulled back significantly due to multiple valuations concerns are now in discounted territory / oversold area GH 79 NTRA 188 HNGE 35

$GH $HNGE My two healthcare growth play. Im in accumulation mode 1. GH Guardant health: Growth • Revenue growth still strong (~20–30% YoY), driven by oncology testing (liquid biopsy) • TAM expanding fast (early cancer detection + recurrence monitoring = multi-billion opportunity) • Volume growth accelerating as adoption improves with oncologists + payors Revenue Quality • Recurring, test-based model → high visibility • Increasing reimbursement coverage = key inflection Valuation • ~$7–8B market cap vs long-term TAM $50B+ (screening optionality not fully priced in) • EV/Sales ~6–8x → reasonable for a category leader with secular growth Bull Case Target • Base: $110–130 • Bull: $150+ (if screening adoption + profitability inflect) 2. HH Hinge health Growth • Hyper-growth digital health (~30–40%+ revenue growth) • Strong enterprise adoption (employers + insurers shifting to cost-saving MSK solutions) • High engagement + outcomes = sticky platform Revenue Quality • SaaS-like recurring contracts • High gross margins (~70%+) → operating leverage story Valuation • Likely trading ~6–9x forward sales (depending on post-IPO levels) • Discount vs top-tier digital health / SaaS comps despite better unit economics Bull Case Target • Base: $35–45 • Bull: $55–65 (if margins scale + growth sustains >30%) GH = deep biotech + long-term optionality (higher risk, higher upside) • HNGE = SaaS-like healthcare disruptor (cleaner story, faster path to profitability) GH = deep biotech + long-term optionality (higher risk, higher upside) • HNGE = SaaS-like healthcare disruptor (cleaner story, faster path to profitability) If market favors AI/biotech innovation → GH wins If market favors profitable growth / SaaS → HNGE wins

$HNGE There are companies Anthropic will demolish. In the panic some companies are getting trampled that should actually be ramping. Hinge is one of them. I will be adding. Great company. Very

$HNGE Bashers and short sellers doesnt have full understanding how this works Company is saving a lot of money by increasing productivity as employees recovers quickly from musculoskeletal injuries.